2011
B Cells as a Therapeutic Target for IFN-β in Relapsing–Remitting Multiple Sclerosis
Ramgolam V, Sha Y, Marcus K, Choudhary N, Troiani L, Chopra M, Markovic-Plese S. B Cells as a Therapeutic Target for IFN-β in Relapsing–Remitting Multiple Sclerosis. The Journal Of Immunology 2011, 186: 4518-4526. PMID: 21368231, DOI: 10.4049/jimmunol.1000271.Peer-Reviewed Original ResearchConceptsRR-MS patientsIFN-β-1bRelapsing-remitting multiple sclerosisCell stimulatory capacityStimulatory capacityB cellsMS patientsUntreated patientsIL-23IL-27IL-12Multiple sclerosisIL-1βProliferative responseAg-specific T cell proliferative responsesFirst-line immunomodulatory therapyT cell proliferative responsesSuppression of CD40Low proliferative responseB-cell secretionCell proliferative responsesB cell functionMHC class IRR-MSImmunomodulatory therapy
2008
Interferon (IFN) beta ‐1a induces IL‐27 and IL‐12, and down‐regulates IL‐23 and IL‐1beta in dendritic cells (DCs), establishing inhibitory conditions for Th‐17 cell differentiation: Implications for treatment of multiple sclerosis (MS)
Ramgolam V, Speer D, Markovic‐Plese S. Interferon (IFN) beta ‐1a induces IL‐27 and IL‐12, and down‐regulates IL‐23 and IL‐1beta in dendritic cells (DCs), establishing inhibitory conditions for Th‐17 cell differentiation: Implications for treatment of multiple sclerosis (MS). The FASEB Journal 2008, 22: 1074.8-1074.8. DOI: 10.1096/fasebj.22.1_supplement.1074.8.Peer-Reviewed Original ResearchIFN beta-1aDendritic cellsIL-27Beta-1aMultiple sclerosisIL-23IL-1 betaIL-1betaPathogenesis of MSIL-23 promotesIL-27 expressionTh-17 cellsMature dendritic cellsInterferon beta-1aIL-1B expressionCytokines IL-6Cytokine gene expressionInduction of SOCS3Cell differentiationSTAT-1 activationExpression of SOCS3STAT-1 geneQuantitative RT-PCRMS patientsStandard therapy